Unicycive Therapeutics (NASDAQ:UNCY) Announces Earnings Results

Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) released its earnings results on Monday. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.10, FiscalAI reports.

Unicycive Therapeutics Price Performance

UNCY opened at $3.70 on Tuesday. The company has a market capitalization of $103.05 million, a PE ratio of -2.11 and a beta of 1.91. Unicycive Therapeutics has a fifty-two week low of $3.33 and a fifty-two week high of $8.74. The business has a 50-day moving average of $4.17 and a 200-day moving average of $5.92.

Analysts Set New Price Targets

A number of research firms have recently issued reports on UNCY. Zacks Research raised shares of Unicycive Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 19th. Benchmark reaffirmed a “speculative buy” rating and set a $15.00 price objective (up from $13.00) on shares of Unicycive Therapeutics in a research report on Thursday, August 20th. B. Riley Financial reiterated a “buy” rating and issued a $20.00 price objective (down from $22.00) on shares of Unicycive Therapeutics in a research note on Wednesday, August 12th. Guggenheim reiterated a “buy” rating and issued a $25.00 price objective (down from $37.00) on shares of Unicycive Therapeutics in a research note on Thursday, August 13th. Finally, HC Wainwright cut their target price on shares of Unicycive Therapeutics from $15.00 to $13.00 and set a “buy” rating for the company in a research report on Tuesday, September 29th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $18.25.

View Our Latest Research Report on UNCY

Unicycive Therapeutics Company Profile

(Get Free Report)

Unicycive Therapeutics is a biopharmaceutical company focused on developing treatments for kidney diseases. Its lead program, oxylanthanum carbonate (OLC), is an oral phosphate binder being developed to help manage hyperphosphatemia, or elevated blood phosphate levels, in people with chronic kidney disease, including patients receiving dialysis. The company is also developing UNI-494, an investigational small-molecule therapy for acute kidney injury. These programs reflect Unicycive’s focus on conditions for which treatment options may be limited.

Read More

Earnings History for Unicycive Therapeutics (NASDAQ:UNCY)

Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.